BeOne Medicines (BEIGF) Long-Term Deferred Tax (2016 - 2023)

BeOne Medicines (BEIGF) has reported Long-Term Deferred Tax for 8 consecutive years, with $2.0 billion the latest figure, recorded in Q4 2023.

• On a quarterly basis, Long-Term Deferred Tax fell 2.38% year-over-year to $2.0 billion in Q4 2023; TTM through Dec 2023 was $2.0 billion, a 2.38% decrease from a year earlier, with the FY2023 full-year figure at $2.0 billion, down 2.38% from the prior year.
• Long-Term Deferred Tax was $2.0 billion for Q4 2023 at BeOne Medicines, down from $2.1 billion in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $2.1 billion in Q4 2022 and troughed at $30.5 million in Q1 2019.
• A 5-year average of $328.5 million and a median of $66.0 million in 2020 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax jumped 155.83% in 2019 and declined 2.38% in 2023, its largest moves.
• Over 5 years, Long-Term Deferred Tax stood at $37.9 million in 2019, then soared by 74.07% to $66.0 million in 2020, then soared by 61.98% to $106.8 million in 2021, then soared by 1846.59% to $2.1 billion in 2022, then retreated by 2.38% to $2.0 billion in 2023.
• The last three Long-Term Deferred Tax figures came in at $2.0 billion (Q4 2023), $2.1 billion (Q4 2022), and $103.4 million (Q2 2022), per Business Quant data.